June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
OCT-based automated vitreous inflammation score: a promising biomarker in dexamethasone implant treated uveitis patients
Author Affiliations & Notes
  • Dominika Pohlmann
    Department of Ophthalmology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
  • Jan Henrik Terheyden
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Moritz Berger
    Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
  • Giovanni Ometto
    Department of Ophthalmology, City, University of London, Optometry and Visual Sciences, London, United Kingdom
  • Giovanni Montesano
    Department of Ophthalmology, City, University of London, Optometry and Visual Sciences, London, United Kingdom
  • Felicitas Neuber
    Department of Ophthalmology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
  • Maximilian W.M. Wintergerst
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Tariq Aslam
    School of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom
  • Xiaoxuan Liu
    University Hospitals Birmingham NHS Foundation Trust, United Kingdom
  • Frank G Holz
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Pearse Andrew Keane
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
  • David P. Crabb
    Department of Ophthalmology, City, University of London, Optometry and Visual Sciences, London, United Kingdom
  • Alastair K Denniston
    Department of Ophthalmology, City, University of London, Optometry and Visual Sciences, London, United Kingdom
  • Robert Finger
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Uwe Pleyer
    Department of Ophthalmology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
  • Footnotes
    Commercial Relationships   Dominika Pohlmann, Allergan (R), Bayer (F); Jan Terheyden, Carl Zeiss MedicTec (F), CenterVue (F), Heidelberg Engineering (F), Optos (F); Moritz Berger, None; Giovanni Ometto, None; Giovanni Montesano, None; Felicitas Neuber, None; Maximilian Wintergerst, CenterVue (F), D-Eye (F), DigiSight Technologies (F), Heidelberg Engineering (F), HEINE Optotechnik GmbH (F), Optos (F), Zeiss Meditec (F); Tariq Aslam, None; Xiaoxuan Liu, None; Frank Holz, Acucela (C), Acucela (R), Allergan (F), Allergan (R), Appelis (C), Appelis (R), Bayer (C), Bayer (F), Bioeq/Formycon (C), Bioeq/Formycon (F), Boehringer-Ingelheim (C), Centervue (F), Ellex (R), Galimedix (C), Geuder (C), Grayburg Vision (C), Grayburg Vision (R), Heidelberg Engineering (F), Heidelberg Engineering (C), Heidelberg Engineering (R), Roche/Genentech (F), Roche/Genentech (C), Roche/Genentech (R); Pearse Keane, Allergan (R), Bayer (S), Bayer (R), Carl Zeiss Meditec (R), DeepMind (C), Haag-Streit (R), Heidelberg Engineering (R), Novartis (S), Novartis (R), Optos (C), Topcon (R); David Crabb, Allergan (R), CentreVue (C), Roche (R), Santen (R); Alastair Denniston, None; Robert Finger, Alimera (C), Bayer (C), CentreVue (F), Ellex (C), Novartis (C), Ophtea (C), Roche/Genentech (C), Santhera (C), Zeiss (F); Uwe Pleyer, Abbvie (C), Alimera (C), Allergan (R), Bayer (C), Bohringer (C), Lilly (C), Novartis (C), Panoptes (R), Roche (R), Santen (R), Thea (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3245. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dominika Pohlmann, Jan Henrik Terheyden, Moritz Berger, Giovanni Ometto, Giovanni Montesano, Felicitas Neuber, Maximilian W.M. Wintergerst, Tariq Aslam, Xiaoxuan Liu, Frank G Holz, Pearse Andrew Keane, David P. Crabb, Alastair K Denniston, Robert Finger, Uwe Pleyer; OCT-based automated vitreous inflammation score: a promising biomarker in dexamethasone implant treated uveitis patients. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3245.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To objectively detect and evaluate vitreous inflammation before and after dexamethasone implant in patients with uveitis by using a recently developed optical coherence tomography (OCT)-based algorithm.

Methods : In this multicenter, retrospective, cross-sectional study, 302 eyes of 223 uveitis patients were included. Clinical and OCT data (Spectralis; Heidelberg Engineering Inc) of all patients were collected. The inflammation score was obtained using an available automated OCT-based algorithm.1 Data of pre and post dexamethasone implantation were compared using a random effects model.

1Montesano, G., Way, C. M., Ometto, G., Ibrahim, H., Jones, P. R., Carmichael, R., Liu, X., Aslam, T., Keane, P. A., Crabb, D. P. & Denniston, A. K. (2018). Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis. Scientific Reports, 8, 1648. doi: 10.1038/s41598-018-20092-y

Results : Patients with cystoid macular edema in uveitis anterior (n=18 eyes), intermediate (n=106 eyes), posterior (n=153 eyes), and panuveitis (n=25 eyes) were treated with a dexamethasone implant. The mean of age was 61 years +/- 15 years and a range of 22 to 88 years. We registered 277 follow-up visits at 1 month (up to 2 months after injection) and 265 follow-up visits at 3 months (>2 months to 4 months). The mean inflammation score at baseline was 0.135, and changed significantly to 0.077 (p<0.0001) 1-2 months and to 0.079 (p<0.0001) 3 months after dexamethasone injection. Correlations with clinical ratings of intraocular inflammation are currently evaluated.

Conclusions : Automated OCT-based objective quantification of vitreous inflammation captures the expected decrease in vitreous inflammation following intravitreal dexamethasone implant. Thus, the automated OCT-based quantification of vitreous inflammation may be a promising alternative and a potentially relevant biomarker compared to current subjective clinical estimates of vitreous inflammation in uveitis.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×